“Omeros Commences Initial Public Offering of Common Stock” (pharmalive.com)
“Elan seals J&J pact as Tysabri battle with Biogen is resolved” (pharmatimes.com)
“The New Ghostbuster: Elsevier Reviews Articles On Wyeth Drugs” (The Pink Sheet)
As part of an effort to prevent ghostwriting in its medical journals, Elsevier is reviewing seven articles it has published on Wyeth’s hormone replacement therapies Premarin and Prempro to see if they satisfy its editorial standards.
This is copyright protected information, to receive the full article, please click here to sign up and register.
“FDA approves Novartis’ Valturna for hypertension” (pharmatimes.com)
“Study Links 45,000 Deaths Each Year to Lack of Insurance” (medpagetoday.com)
“”High number” of potential buyers as sale of Ratiopharm begins” (pharmatimes.com)
“From Ancient Bones to the Future of DNA Technologies: Forensic Experts Gather for Exclusive Symposium on Human Identity” (stockpoint.com)
“New Appointments at London Genetics to Drive Strategy Forward” (stockpoint.com)
SUBSCRIBE